Several countries in Europe are now discouraging giving puberty blockers to children as the “outlier” U.S. continues to defend the treatment, according to a new report.
The United Kingdoms National Health Service limited the use of puberty blockers for clinical research this month, according to its website, citing “significant uncertainties surrounding the use of hormone treatments.”
“We are now going out to targeted stakeholder testing on an interim clinical commissioning policy proposing that, outside of a research setting, puberty suppressing hormones should not be routinely commissioned for children and adolescents who have gender incongruence/dysphoria,” the UK’s NHS website reads.
The U.S. medical community largely believes the science behind transgender medical treatments is settled, according to the Wall Street Journal, writing, “The U.S. is becoming an outlier among many Western nations in the way its national medical institutions treat children suffering from distress over…